Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will present 12-month Phase 2 results for its OCU410 gene therapy in geographic atrophy at a scientific meeting in September, putting new clinical …
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) extended its expected cash runway into 2028 with a $130 million convertible debt financing as the biotechnology company moves one retinal gene therapy …
Ocugen Raises $130 Million as Gene Therapy Trials Advance Read More MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will report second-quarter 2026 financial results before the market opens Aug. 6 and hold a conference call later that morning to discuss its …
Ocugen Sets Aug. 6 Earnings Call With Business Update Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) has signed a binding term sheet that could generate up to $259 million in licensing and sales milestone payments, plus ongoing royalties, as …
Ocugen Targets $259 Million in MENA Licensing Deal for OCU400 Read More MALVERN, PA — Ocugen (NASDAQ: OCGN) will present updates on its modifier gene therapy platform and clinical data from its retinal disease programs at a series of investor and industry …
Ocugen to Present Gene Therapy Data at July Conferences Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) recently closed a $130 million private offering of convertible senior notes, using part of the proceeds to retire existing debt while extending its …
Ocugen Extends Cash Runway With $130 Million Notes Read More MALVERN, PA — Ocugen (NASDAQ: OCGN) reported positive mid-stage clinical data for its geographic atrophy gene therapy program while raising additional capital expected to fund operations into 2028 as the …
Ocugen Reports Positive GA Trial Data, Extends Cash Runway Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More